Three drugs together for kidney cancer that has spread to the brain
Official title: A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests three cancer drugs given together for kidney cancer that has spread to the brain.
Read our full plain-language summary
What the trial team says
A Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases
Key facts
- Registry number
- NCT05048212
- Stage of testing
- Phase 2
- Conditions studied
- Brain Metastases, Renal Cell Carcinoma
Where it is running
This trial lists 1 site.
-
Texas
- M D Anderson Cancer Center (Houston)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.